

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Release of Security Interest
CONVEYING PARTY DATA	
Name	Execution Date
GOLDMAN SACHS CREDIT PARTNERS L.P., AS COLLATERAL AGENT	03/09/2007
RECEIVING PARTY DATA	
Name:	RELIANT PHARMACEUTICALS, INC.
Street Address:	110 ALLEN ROAD
City:	LIBERTY CORNER
State/Country:	NEW JERSEY
Postal Code:	07938
PROPERTY NUMBERS Total: 47	
Property Type	Number
Patent Number:	4375547
Patent Number:	4904792
Patent Number:	5334725
Patent Number:	5457206
Patent Number:	4587344
Patent Number:	4777260
Patent Number:	5470865
Patent Number:	4466972
Patent Number:	4567271
Patent Number:	4816263
Patent Number:	4946687
Patent Number:	4950486
Patent Number:	5030456
Patent Number:	5082668
Patent Number:	4945114

501243486

PATENT
REEL: 024741 FRAME: 0060

OP \$1880.00 4375547

Patent Number:	5681588
Patent Number:	6500454
Patent Number:	6663888
Patent Number:	5502077
Patent Number:	5656667
Patent Number:	5698594
Patent Number:	7048945
Patent Number:	6627223
Application Number:	10875627
Application Number:	10689566
Application Number:	10453848
Application Number:	10335295
Application Number:	11239687
Application Number:	11615163
Application Number:	11432670
Application Number:	11432671
Application Number:	11432661
Application Number:	11292305
Application Number:	11377648
Application Number:	11333387
Application Number:	11106482
Application Number:	10979751
Application Number:	10792918
Application Number:	09869333
Application Number:	11649881
Application Number:	11494799
Application Number:	11488181
Application Number:	11370178
Application Number:	11293513
Application Number:	11293496
Application Number:	11284095
Application Number:	11267581

CORRESPONDENCE DATA

Fax Number: (866)826-5420

PATENT
REEL: 024741 FRAME: 0061

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 3016380511
Email: ipresearchplus@comcast.net
Correspondent Name: IP Research Plus, Inc.
Address Line 1: 21 Tadcaster Circle
Address Line 2: Attn: Penelope J.A. Agodoa
Address Line 4: Waldorf, MARYLAND 20602

ATTORNEY DOCKET NUMBER:

35939

NAME OF SUBMITTER:

Penelope J.A. Agodoa

Total Attachments: 7

source=35939#page1.tif

source=35939#page2.tif

source=35939#page3.tif

source=35939#page4.tif

source=35939#page5.tif

source=35939#page6.tif

source=35939#page7.tif

PATENT RELEASE OF SECURITY INTEREST

THIS RELEASE dated as of December 18, 2007 by Goldman Sachs Credit Partners L.P., as Collateral Agent (as defined below) for the Lenders. Terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Credit and Guaranty Agreement or Security Agreements referred to below.

A. Reference is made to the Credit and Guaranty Agreement dated as of March 9, 2007 (as amended, supplemented or otherwise modified prior to the date hereof, the "Credit and Guaranty Agreement"), among Reliant Pharmaceuticals, Inc. (the "Borrower"), certain subsidiaries of the Borrower, the lenders from time to time parties thereto (the "Lenders"), Goldman Sachs Credit Partners L.P. ("GSCP") as lender, sole lead arranger, sole bookrunner and syndication agent, as collateral agent and as administrative agent for the Lenders thereunder (together with its permitted successors in such capacity, the "Administrative Agent").

B. Reference is made to (i) the Pledge and Security Agreement dated as of March 9, 2007 (as amended, supplemented or otherwise modified prior to the date hereof, the "Pledge and Security Agreement"), among the Borrower, any Additional Grantor as defined therein and GSCP, as collateral agent (in such capacity, the "Collateral Agent") and (ii) the Patent Security Agreement dated as of March 9, 2007, among the Borrower, RPSUB No. 3(R), Inc., RPSUB No. 4(I), Inc., RPSUB No. 5(D), Inc., RPSUB No. 6(O), Inc. (collectively, the "Grantors") and the Collateral Agent (as amended, supplemented or otherwise modified prior to the date hereof, the "Patent Security Agreement" and, together with the Pledge and Security Agreement, the "Security Agreements").

C. Pursuant to the Security Agreements, among other things, the Grantors granted a security interest to the Collateral Agent, for the benefit of the Secured Parties, in, among other things, the patents, patent applications and patent licenses of the Grantors set forth on Schedule I hereto (the "Patents"), which security interest was recorded with the United States Patent & Trademark Office on May 9, 2007 at Reel 019265, Frame 0086.

D. In connection with the termination of the Credit Agreement, the Borrower has satisfied all of its obligations under the Credit and Guaranty Agreement and has informed the Collateral Agent of its desire to obtain the release of all right, title and interest of the Collateral Agent, the Secured Parties and each other grantee or beneficiary in and to the Patents granted under the Security Agreements.

Accordingly, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, all the Collateral Agent's existing or hereafter acquired right, title and interest (including, without limitation, security interests) in and to the Patents pursuant to the Security Agreements, including, without limitation, the Patents set forth on Schedule I attached hereto, shall automatically terminate as provided in the Security Agreements, and the Collateral Agent hereby terminates, releases and discharges its security interest in the Patents.


THIS LETTER AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the Collateral Agent has caused this Release to be duly executed by its duly authorized officer as of the day and year above written.

GOLDMAN SACHS CREDIT PARTNERS
L.P., as Collateral Agent,

By



Name:

Elizabeth Fischer

Title:

Authorized Signatory

PATENTS

Regulatory Approvals

<u>Product</u>	<u>NDA#</u>
Axid	19-508
DynaCirc®	19-546
Dynacirc CR®	20-336
Rythmol®	19-151
Rythmol® SR	21-416
Innopran® XL	21-438
Omacor®	21-654

Patents (Issued)

<u>Product</u>	<u>Patent #</u>	<u>Interest</u>
Axid	4,375,547	Assigned
	4,904,792	Licensed
	5,334,725	Licensed
	5,457,206	Licensed
	4,587,344	Licensed
	4,777,260	Licensed
	5,470,865	Licensed
	PCTUS05/40230	Owned
DynaCirc CR®	4,466,972	Assigned
	4,567,271	Assigned
	4,816,263	Licensed
	4,946,687	Licensed
	4,950,486	Licensed
	5,030,456	Licensed
	5,082,668	Licensed
Rythmol® SR	4,945,114	Assigned
	5,681,588	Assigned
Innopran® XL	6,500,454	Licensed
	6,663,888	Licensed
Omacor®	5,502,077	Licensed
	5,656,667	Licensed
	5,698,594	Licensed

Patents (Application)

<u>Product</u>	<u>Patent #</u>	<u>Interest</u>
Innopran® XL	10/875,627	Licensed
	10/689,566	Licensed
	10/453,848	Licensed
	10/335,295	Licensed
	7/048,945	Licensed
	6/663,888	Licensed
	6,627,223	Licensed
	11/239,687	Owned
	PCTUS05/035198	Owned
DynaCirc® CR	60/841,496 (Provisional)	Owned
	US 11/615,163	Owned
	US 11/432,670	Owned
	US 11/432,671	Owned
	US 11/432,661	Owned
	US 11/377,648	Owned
	US 11/292,305	Owned
DynaCirc BXR	US 11/377,648	Owned
Omacor®	11/333,387	Licensed
	11/106,482	Licensed
	10/979,751	Licensed
	10/792,918	Licensed
	09/869,333	Licensed
	60/856,299 (Provisional)	Licensed
	60/856,300 (Provisional)	Licensed
	US 11/649,881	Owned
	PCTUS07/00224	Owned
	US 11/494,799	Owned
	PCTUS06/29217	Owned
	US 11/488,181	Owned
	PCTUS06/27726	Owned
	US 11/370,178	Owned
	PCTUS06/08404	Owned
	US 11/293,513	Owned
	PCTUS05/44035	Owned
	US 11/293,496	Owned
	PCTUS05/44036	Owned
	US 11/284,095	Owned
	PCTUS05/42648	Owned
	US 11/267,581	Owned

PCT__[# not yet assigned *]	Owned
60/780,306 (Provisional)	Owned
60/832,156 (Provisional)	Owned
60/832,123 (Provisional)	Owned
60/836,976 (Provisional)	Owned
60/840,012 (Provisional)	Owned
60/850,280 (Provisional)	Owned
60/851,294 (Provisional)	Owned
60/852,398 (Provisional)	Owned
60/856,299 (Provisional)	Owned
60/856,300 (Provisional)	Owned
60/856,832 (Provisional)	Owned
60/860,495 (Provisional)	Owned
60/861,244 (Provisional)	Owned
60/880,441 (Provisional)	Owned
60/897,508 (Provisional)	Owned

*Methods of Identifying and Treating Patients Likely to Benefit from Omega-3 Fatty Acid Therapy for Dementia, Vascular Dementia, Parkinson's Dementia, Alzheimer's Disease, and/or Mild Cognitive Impairment [Filed February 16, 2007 with priority to February 16, 2006].